669 related articles for article (PubMed ID: 17383140)
21. [Patterns of susceptibility to antibiotics of Enterobacteriaceae causing intra-abdominal infection in Spain: SMART 2003 study outcomes].
Baquero F; Cercenado E; Cisterna R; de la Rosa M; García-Rodríguez JA; Gobernado M; Pérez JL; Manchado P; Martín R; Pascual A; Picazo J; Prats G; Rubio C; Snyder TA; Sanz-Rodríguez C
Rev Esp Quimioter; 2006 Mar; 19(1):51-9. PubMed ID: 16688292
[TBL] [Abstract][Full Text] [Related]
22. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003).
Johnson DM; Stilwell MG; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2006 Sep; 56(1):69-74. PubMed ID: 16546341
[TBL] [Abstract][Full Text] [Related]
23. Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004).
Deshpande LM; Sader HS; Debbia E; Nicoletti G; Fadda G; Jones RN;
Diagn Microbiol Infect Dis; 2006 Mar; 54(3):157-64. PubMed ID: 16423493
[TBL] [Abstract][Full Text] [Related]
24. Bactericidal activity of garenoxacin tested by kill-curve methodology against wild type and QRDR mutant strains of Streptococcus pneumoniae.
Anderegg TR; Jones RN
Diagn Microbiol Infect Dis; 2004 Nov; 50(3):213-7. PubMed ID: 15541608
[TBL] [Abstract][Full Text] [Related]
25. Potency and spectrum reevaluation of cefdinir tested against pathogens causing skin and soft tissue infections: a sample of North American isolates.
Sader HS; Streit JM; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2004 Aug; 49(4):283-7. PubMed ID: 15313534
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
Hansen GT; Blondeau JM
J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
[TBL] [Abstract][Full Text] [Related]
27. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
28. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).
Rhomberg PR; Jones RN
Diagn Microbiol Infect Dis; 2007 Feb; 57(2):207-15. PubMed ID: 16949243
[TBL] [Abstract][Full Text] [Related]
29. High rates of antimicrobial co-resistance among Enterobacteriaceae: comparative analysis between clinical isolates resistant and susceptible to third-generation cephalosporins.
Goyanes MJ; Cercenado E; Insa R; Morente A; Alcalá L; Bouza E
Rev Esp Quimioter; 2007 Jun; 20(2):216-21. PubMed ID: 17893759
[TBL] [Abstract][Full Text] [Related]
30. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008).
Rhomberg PR; Jones RN
Diagn Microbiol Infect Dis; 2009 Dec; 65(4):414-26. PubMed ID: 19833471
[TBL] [Abstract][Full Text] [Related]
31. Activity of gatifloxacin tested against isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (North America, 1998-2003).
Fedler KA; Jones RN; Sader HS; Fritsche TR
Diagn Microbiol Infect Dis; 2006 Jun; 55(2):157-64. PubMed ID: 16529904
[TBL] [Abstract][Full Text] [Related]
32. Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005-2009).
Sader HS; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2011 Feb; 69(2):223-7. PubMed ID: 21251571
[TBL] [Abstract][Full Text] [Related]
33. Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Pfaller MA; Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2006 Sep; 56(1):63-8. PubMed ID: 16650951
[TBL] [Abstract][Full Text] [Related]
34. Activity of gemifloxacin tested against Neisseria gonorrhoeae isolates including antimicrobial-resistant phenotypes.
Pottumarthy S; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2006 Feb; 54(2):127-34. PubMed ID: 16423492
[TBL] [Abstract][Full Text] [Related]
35. Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001).
Jones RN; Biedenbach DJ
Diagn Microbiol Infect Dis; 2003 Apr; 45(4):273-8. PubMed ID: 12729999
[TBL] [Abstract][Full Text] [Related]
36. Clonal occurrences of multidrug-resistant Gram-negative bacilli: report from the Meropenem Yearly Susceptibility Test Information Collection Surveillance Program in the United States (2004).
Rhomberg PR; Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2006 Apr; 54(4):249-57. PubMed ID: 16466890
[TBL] [Abstract][Full Text] [Related]
37. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Moet GJ; Jones RN; Biedenbach DJ; Stilwell MG; Fritsche TR
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):7-13. PubMed ID: 17059876
[TBL] [Abstract][Full Text] [Related]
38. Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents.
Pottumarthy S; Fritsche TR; Sader HS; Stilwell MG; Jones RN
Int J Antimicrob Agents; 2005 Apr; 25(4):282-9. PubMed ID: 15784306
[TBL] [Abstract][Full Text] [Related]
39. Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolates.
Adam HJ; Schurek KN; Decorby MR; Weshnoweski B; Vashisht R; Karlowsky K; Hoban DJ; Zhanel GG
J Antimicrob Chemother; 2006 Jul; 58(1):202-4. PubMed ID: 16636082
[TBL] [Abstract][Full Text] [Related]
40. [Comparative in vitro activity of garenoxacin (BMS-284756). Sentry program, Spain (1999-2000)].
Loza E; Cantón R; Pascual A; Tubau F; Morosini MI; Almaraz F; Perea E; Martín R; Jones RN; Baquero F
Enferm Infecc Microbiol Clin; 2003 Oct; 21(8):404-9. PubMed ID: 14525705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
